Novel tumour markers: a diagnostic role in pancreatic cancer?
作者信息
Roulston J E
出版信息
Br J Cancer. 1994 Sep;70(3):389-90. doi: 10.1038/bjc.1994.313.
Abstract
摘要
相似文献
1
Novel tumour markers: a diagnostic role in pancreatic cancer?新型肿瘤标志物：在胰腺癌诊断中的作用？
Br J Cancer. 1994 Sep;70(3):389-90. doi: 10.1038/bjc.1994.313.
2
[Tumour markers of pancreatic cancer (tumour associated antigens)].[胰腺癌的肿瘤标志物（肿瘤相关抗原）]
Pol Arch Med Wewn. 2005 Jun;113(6):585-93.
3
A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.一项关于血清肿瘤标志物癌胚抗原、糖类抗原50和242、组织多肽抗原及组织多肽特异性抗原在胰腺癌诊断中的前瞻性研究，特别提及多变量诊断评分。
Br J Cancer. 1994 Mar;69(3):562-5. doi: 10.1038/bjc.1994.102.
4
Serum CA 242: the search for a valid marker of pancreatic cancer.血清CA 242：寻找胰腺癌的有效标志物。
Clin Chem Lab Med. 1998 Mar;36(3):179-84. doi: 10.1515/CCLM.1998.033.
5
CA50 as a serum marker for pancreatic carcinoma: comparison with CA19-9.CA50作为胰腺癌的血清标志物：与CA19-9的比较。
Eur J Cancer. 1994;30A(7):1042-3. doi: 10.1016/0959-8049(94)90154-6.
6
Clinical relevance of tumour markers CA 19-9 and CA-50 in sera from patients with pancreatic duct carcinoma.胰腺导管癌患者血清中肿瘤标志物CA 19-9和CA-50的临床相关性
Surg Oncol. 1992 Apr;1(2):109-13. doi: 10.1016/0960-7404(92)90023-e.
7
Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.一种新型血清肿瘤标志物CA 242在胰腺癌中的临床评估
Br J Cancer. 1992 May;65(5):731-4. doi: 10.1038/bjc.1992.154.
8
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.CA 242，一种新型胰腺癌肿瘤标志物：与CA 19-9、CA 50和癌胚抗原的比较。
Br J Cancer. 1994 Sep;70(3):487-92. doi: 10.1038/bjc.1994.332.
9
Meta-analysis of diagnostic value of serum Carbohydrate antigen 199 in pancreatic cancer.血清糖类抗原199在胰腺癌诊断价值中的Meta分析。
Minerva Med. 2016 Feb;107(1):62-9. Epub 2016 Jan 29.
10
Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.诊断陷阱；肝功能不全时CA 19-9浓度的解读
Gut. 1994 May;35(5):707-8. doi: 10.1136/gut.35.5.707.
引用本文的文献
1
Serum tumor markers in pancreatic cancer-recent discoveries.血清肿瘤标志物在胰腺癌中的最新发现。
Cancers (Basel). 2010 Jun 2;2(2):1107-24. doi: 10.3390/cancers2021107.
本文引用的文献
1
A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.一项关于血清肿瘤标志物癌胚抗原、糖类抗原50和242、组织多肽抗原及组织多肽特异性抗原在胰腺癌诊断中的前瞻性研究，特别提及多变量诊断评分。
Br J Cancer. 1994 Mar;69(3):562-5. doi: 10.1038/bjc.1994.102.
2
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.CA 242，一种新型胰腺癌肿瘤标志物：与CA 19-9、CA 50和癌胚抗原的比较。
Br J Cancer. 1994 Sep;70(3):487-92. doi: 10.1038/bjc.1994.332.
3
Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.CA242与CA19-9用于胰腺癌诊断的比较研究
Br J Cancer. 1994 Sep;70(3):481-6. doi: 10.1038/bjc.1994.331.
4
Reflections on biochemical aspects of human cancer. The Lucy Wortham James Lecture.关于人类癌症生化方面的思考。露西·沃瑟姆·詹姆斯讲座。
Cancer. 1974 Feb;33(2):364-70. doi: 10.1002/1097-0142(197402)33:2<364::aid-cncr2820330210>3.0.co;2-3.
5
Limitations of tumour markers in screening.肿瘤标志物在筛查中的局限性。
Br J Surg. 1990 Sep;77(9):961-2. doi: 10.1002/bjs.1800770903.
6
Zotero 插件